REPLIGEN CORPORATION - COMMON STOCK
146.39
25-November-24 14:05:35
15 minutes delayed
Stocks
+3.81
+2.67%
Today's range
142.73 - 148.03
ISIN
N/A
Source
NASDAQ
-
Repligen Appoints Martin D. Madaus to Board of Directors
09 Feb 2023 07:30:00 By Nasdaq GlobeNewswire
-
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
08 Feb 2023 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Corporation to Present at Upcoming Investor Conferences
08 Nov 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
01 Nov 2022 07:30:01 By Nasdaq GlobeNewswire
-
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
01 Nov 2022 07:00:01 By Nasdaq GlobeNewswire
-
Repligen to Report Third Quarter 2022 Financial Results
12 Oct 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
19 Sep 2022 16:01:00 By Nasdaq GlobeNewswire
-
Repligen To Host Investor Day 2022
24 Aug 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
02 Aug 2022 07:30:01 By Nasdaq GlobeNewswire
-
Repligen to Report Second Quarter 2022 Financial Results
19 Jul 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
26 May 2022 16:30:00 By Nasdaq GlobeNewswire
-
Repligen Corporation to Present at Upcoming Investor Conferences
25 May 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
27 Apr 2022 07:30:01 By Nasdaq GlobeNewswire
-
Repligen to Report First Quarter 2022 Financial Results
13 Apr 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
18 Mar 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
17 Feb 2022 07:30:01 By Nasdaq GlobeNewswire
-
Repligen Launches AAV Affinity Resins for Gene Therapy Purification
15 Feb 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference
11 Feb 2022 07:30:00 By Nasdaq GlobeNewswire
-
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
03 Feb 2022 09:30:09 By Nasdaq GlobeNewswire